Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAV | P06756 | 20/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 19/20 | 0.47 |
| ▸ | ITGB5 | P18084 | 7/20 | 0.47 |
| ▸ | ITGB6 | P18564 | 5/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.47 |
| ▸ | ITGB8 | P26012 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7374387 | 0.91 | ITGAV (0.54) | ITGAVITGB3ITGB5ITGB6ITGA2B | |
| SCHEMBL7995004 | 0.86 | ITGAV (0.58) | ITGAVITGB3ITGB5ITGB6ITGA2B | |
| SCHEMBL7995248 | 0.77 | ITGAV (0.68) | ITGAVITGB3ITGB5ITGB6ITGA2B | |
| SCHEMBL7912469 | 0.75 | ITGB3 (0.56) | ITGAVITGB3ITGB5ITGA2B | |
| SCHEMBL6421324 | 0.74 | ITGB3 (0.67) | ITGAVITGB3ITGB5ITGB6ITGB8 | |
| SCHEMBL6421320 | 0.74 | ITGB3 (0.67) | ITGAVITGB3ITGB5ITGB6ITGB8 | |
| SCHEMBL6265738 | 0.73 | ITGAV (0.56) | ITGAVITGB3ITGB5ITGB6ITGA2B | |
| SCHEMBL7380579 | 0.73 | ITGB3 (0.61) | ITGAVITGB3ITGB5ITGB6ITGA2B | |
| SCHEMBL29154194 | 0.73 | ITGAV (0.54) | ITGAVITGB3ITGB5ITGB6ITGA2B | |
| SCHEMBL20141513 | 0.72 | ITGAV (0.55) | ITGAVITGB3ITGB5ITGB6ITGB8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6294549-B1 | COMPOUNDS USEFUL FOR INHIBITING RESTENOSIS, ANGIOGENESIS, ATHEROSCLEROSIS, DIABETIC RETINOPATHY, MACULAR DEGENERATION, INFLAMMATION OR TUMOR GROWTH. | MERCK & CO., INC. | 2001-09-25 | — | — | US | claimed |
| EP-0880511-A4 | INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 1999-06-16 | — | — | EP | claimed |
| EP-0880511-A1 | INTEGRIN RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 1998-12-02 | — | — | EP | claimed |
| WO-1997026250-A1 | INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1997-07-24 | — | — | WO | claimed |
| US-6294549-B1 | COMPOUNDS USEFUL FOR INHIBITING RESTENOSIS, ANGIOGENESIS, ATHEROSCLEROSIS, DIABETIC RETINOPATHY, MACULAR DEGENERATION, INFLAMMATION OR TUMOR GROWTH. | MERCK & CO., INC. | 2001-09-25 | — | — | US | disclosed |
| US-5952306-A | INHIBITING THE BINDING OF FIBRINOGEN TO BLOOD PLATELETS AND INHIBITING THE AGGREGATION OF BLOOD PLATELETS; INHIBITING OSTEOCLAST CELLULAR ADHESION TO BONE SURFACES | MERCK & CO., INC. (US) | 1999-09-14 | — | — | US | disclosed |
| EP-0880511-A4 | INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 1999-06-16 | — | — | EP | disclosed |
| EP-0880511-A1 | INTEGRIN RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 1998-12-02 | — | — | EP | disclosed |
| WO-1997026250-A1 | INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1997-07-24 | — | — | WO | disclosed |